Former Apple Engineers’ Physical AI Startup Lyte Raises $165M At $1.6B Valuation
THE SO WHAT
Lyte’s $165M Series C at a $1.6B valuation for robot sensing and perception shows capital is flowing into the “eyes and brainstem” of physical AI, not just humanoid bodies. If you’re buying or building robots, expect perception stacks to become a major vendor selection axis—on par with form factor and end‑effector.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureAm I a fake founder? What it’s like joining a startup as a cofounder a year late
Late-stage cofounders are increasingly a structural tool — a way to bolt on missing skills, credibility, or networks once the company has real signal. If you’re an early team or investor, be explicit in paper and in culture about what ‘founder’ means, or you’ll store up resentment and misaligned expectations for the first real stress event.
Startups & VentureExclusive: Legaltech Lexroom seals first two M&A deals four months after $50m Series B
Lexroom moving to M&A just four months after a $50m Series B says legaltech is consolidating into platforms, not point tools. If you’re building or buying in this category, underwrite against roll-up dynamics — either become an acquirer or design your product and contracts to be an easy plug-in for one.
Startups & VentureFirmus to Start Investor Meetings for Australia IPO, AFR Says
Firmus kicking off investor meetings for an Australian IPO is another data point that public markets are reopening selectively for tech. If you’re a late-stage company in that region, treat this as a pricing test — watch valuation multiples and demand quality before you lock in your own timing.
Startups & VentureAnthropic Said to Walk Away From $6 Billion Decart Acquisition
Walking away from a reported $6B deal is a reminder that top labs are still selective about inorganic bets — talent and IP are abundant enough that overpaying for one startup is optional. If you’re building in the AI tooling or infra layer, assume partnership and distribution deals may be more realistic than a near-term lab acquisition.